Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study

被引：0
|
作者：
Cortot, A. [1 ]
Escande, F. [1 ]
Gervais, R. [2 ]
Greillier, L. [3 ]
Corre, R. [4 ]
Veillon, R. [5 ]
Ionescu, M. [6 ]
Felicio, H. [6 ]
Pau, D. [6 ]
Gregoire, V. [1 ]
Girard, N. [7 ]
机构：
[1] Univ Lille, CHU Lille, Inst Pasteur Lille, Cnrs,Inserm,Umr9020,Umr S 1277,Canther, Lille, France
[2] Ctr Francois Baclesse, Caen, France
[3] Aix Marseille Univ, Marseille, France
[4] Ch Cornouaille, Quimper, France
[5] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[6] Labs Roche, Boulogne, France
[7] Inst Curie, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
non-small cell lung cancer; ALK; Alectinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.06
引用
收藏
页码：S658 / S658
页数：1
相关论文
共 50 条
  • [21] Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study
    Lin, J. J.
    Muzikansky, A.
    Kennedy, E.
    Kuberski, H.
    Stober, L. L.
    Wanat, A. C.
    Azzoli, C. G.
    Lennes, I
    Sequist, L., V
    Dagogo-Jack, I
    Shaw, A. T.
    Gainor, J. F.
    ESMO OPEN, 2022, 7 (01)
  • [22] Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results
    Lococo, F.
    Chiappetta, M.
    Cancellieri, A.
    Cardillo, G.
    Zanelli, F.
    Mangiameli, G.
    Toschi, L.
    Guggino, G.
    Romano, F.
    Leuzzi, G.
    Proto, C.
    Spaggiari, L.
    De Marinis, F.
    Vita, E.
    Menna, E.
    Margaritora, S.
    Bria, E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S297 - S297
  • [23] Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
    Tamura, T.
    Seto, T.
    Nakagawa, K.
    Maemondo, M.
    Inoue, A.
    Hida, T.
    Yoshioka, H.
    Harada, M.
    Ohe, Y.
    Nogami, N.
    Murakami, H.
    Takeuchi, K.
    Asakawa, T.
    Kikuchi, K.
    Tanaka, T.
    Nishio, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S6 - S6
  • [24] Efficacy and survival outcomes of alectinib vs. crizotinib in ALK-positive NSCLC patients with CNS metastases: A retrospective study
    Liu, Qing
    Fu, Ying
    Guo, Jun
    Fu, Chunqiu
    Tang, Ning
    Zhang, Chufeng
    Han, Xiao
    Wang, Zhehai
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [25] Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results
    Lococo, Filippo
    Cancellieri, Alessandra
    Chiappetta, Marco
    Leonetti, Alessandro
    Cardillo, Giuseppe
    Zanelli, Francesca
    Mangiameli, Giuseppe
    Toschi, Luca
    Guggino, Gianluca
    Romano, Francesco Jacopo
    Leuzzi, Giovanni
    Proto, Claudia
    Spaggiari, Lorenzo
    De Marinis, Filippo
    Vita, Emanuele
    Ampollini, Luca
    Margaritora, Stefano
    Tiseo, Marcello
    Bria, Emilio
    CLINICAL LUNG CANCER, 2023, 24 (05) : 467 - 473
  • [26] PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN JAPANESE PATIENTS WITH ADVANCED, ALK-REARRANGED NSCLC AND OTHER TUMORS HARBORING GENETIC ALK ALTERATIONS
    Seto, Takashi
    Murakami, Haruyasu
    Hirai, Fumihiko
    Horiike, Atsushi
    Takahashi, Toshiaki
    Suenaga, Naoko
    Tajima, Takeshi
    Tokushige, Kota
    Boral, Anthony
    Robson, Matthew
    Nishio, Makoto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S595 - S596
  • [27] Overall survival results of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC (ASCEND-3)
    Felip, E.
    Nishio, M.
    Orlov, S.
    Park, K.
    Yu, C-J.
    Tsai, C-M.
    Cobo, M.
    McKeage, M.
    Su, W-C.
    Mok, T. S. K.
    Scagliotti, G. V.
    Spigel, D.
    Passos, V. Q.
    Chen, Z.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2018, 29 : 745 - 745
  • [28] A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK plus NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.
    Ohe, Yuichiro
    Nishio, Makoto
    Kiura, Katsuyuki
    Seto, Takashi
    Nakagawa, Kazuhiko
    Maemondo, Makoto
    Inoue, Akira
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Harada, Masao
    Nogami, Naoyuki
    Murakami, Haruyasu
    Takeuchi, Kengo
    Shimada, Tadashi
    Kuriki, Hiroshi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
    De Castro, Gilberto, Jr.
    Tan, Daniel Shao-Weng
    Crino, Lucio
    Wu, Yi Long
    Paz-Ares, Luis
    Wolf, Juergen
    Geater, Sarayut
    Orlov, Sergey
    Cortinovis, Diego
    Yu, Chong-Jen
    Hochmair, Maximilian
    Cortot, Alexis
    Tsai, Chun-Ming
    Moro-Sibilot, Denis
    Campelo, Rosario Garcia
    Branle, Fabrice
    Sen, Paramita
    Mcculloch, Tracey
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S7 - S7
  • [30] Alectinib vs crizotinib in treatment-naive ALK plus NSCLC: CNS efficacy results from the ALEX study
    Gadgeel, S.
    Peters, S.
    Mok, T. S. K.
    Shaw, A. T.
    Kim, D-W.
    Ou, S-H. I.
    Perol, M.
    Dziadziuszko, R.
    Ahn, J. S.
    Rosell, R.
    Zeaiter, A.
    Mitry, E.
    Nueesch, E.
    Balas, B.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
12345